HC Wainwright Reaffirms “Buy” Rating for BiomX (NYSEMKT:PHGE)

HC Wainwright restated their buy rating on shares of BiomX (NYSEMKT:PHGE) in a report released on Monday, Benzinga reports. They currently have a $2.00 price objective on the stock.

BiomX Stock Down 2.2 %

Shares of BiomX stock opened at $0.34 on Monday. The company has a current ratio of 2.84, a quick ratio of 2.84 and a debt-to-equity ratio of 0.51. The business’s 50 day moving average is $0.32 and its two-hundred day moving average is $0.31. The firm has a market capitalization of $18.72 million, a PE ratio of -0.64 and a beta of 1.36.

BiomX Company Profile

BiomX Inc, a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC).